Huntington’s Disease Society of America (HDSA) leaders at the group’s 41st annual convention unveiled a new strategic plan and mission statement to meet the needs of Huntington’s disease patients, including plans to expand research programs and Centers of Excellence and build a strong network to fight the disease.
News
Teva Pharmaceuticals’ Austedo (deutetrabenazine) and its extended-release formulation, Austedo XR — approved to treat chorea, or involuntary movements, in people with Huntington’s disease — have functional and social benefits for both patients and their caregivers. That’s according to real-world data presented today by Debbi Fox-Davis, Teva‘s director…
The 41st Huntington’s Disease Society of America (HDSA) convention kicks off today in Phoenix, bringing together a sold-out crowd of patients, caregivers, families, and researchers. Running through Saturday, the three-day annual event focuses on providing practical support for navigating life with Huntington’s disease, with some sessions…
UniQure plans to ask the U.S Food and Drug Administration (FDA) for accelerated approval of AMT-130 to treat Huntington’s disease in the next few months, after the agency dropped its request for a new clinical trial. The agency agreed in a recent meeting that the three-year analysis from two…
Blocking an inflammatory pathway in the brain called cGAS-STING may slow the progression of Huntington’s disease, according to a study using a mouse model of the disease. Disrupting this pathway, either by deleting the cGAS gene or using an experimental small-molecule compound that suppresses STING, reduced brain inflammation and…
The approved oral medication Austedo (deutetrabenazine) or its extended-release formulation Austedo XR can help reduce the impact of Huntington’s disease-associated chorea, or involuntary movements, on patients’ daily activities and social interactions, while also easing the emotional and social burden on caregivers. Those are the findings of a U.S.
Interim clinical trial data suggest people with early-stage Huntington’s disease who were treated with the investigational oral therapy SKY-0515 for up to one year had slower disease progression than would be expected based on natural history data. That’s according to new interim data from Part C of a…
Smartphone-recorded speech may provide a simple and less burdensome way to assess disease severity in people with Huntington’s disease, a small study suggests. Researchers found that fully automated analysis of language patterns using speech-recognition and language-analysis tools could statistically predict motor, cognitive, and functional scores with moderate to strong predictive…
Apathy, a common symptom of Huntington’s disease, may present even before the development of hallmark motor symptoms and worsens gradually over time, according to a six-year study of people carrying a Huntington’s-causing mutation. Data also showed that in those without clear Huntington’s symptoms, apathy worsening over time was mainly…
The first participant has been dosed in a large clinical trial testing the experimental oral therapy votoplam (formerly PTC518) in adults with early-stage Huntington’s disease. That’s according to a press release from PTC Therapeutics, the therapy’s original developer, announcing its latest financial results and business updates.
Recent Posts
- Tips for achieving restorative sleep while living with Huntington’s disease
- New quality of life questionnaire aims to give voice to Huntington’s patients
- It’s time to start fixing our country’s gaps in healthcare access
- Planning for the future is complicated with Huntington’s disease
- Global clinical trial testing Huntington’s pill to open in 3 new countries